(Crain’s) — The torrid growth of Abbott Laboratories’ rheumatoid arthritis drug, Humira, has cooled in recent months, stoking investors’ concerns over how long the blockbuster medication can drive the drugmaker’s profit growth. North Chicago-based Abbott on Wednesday reported ...
